Bio-Techne Corporation (NASDAQ:TECH) Q2 2020 Earnings Conference Call February 4, 2020 9:00 AM ET Company Participants David Clair - Senior Director, Corporate Development Charles Kummeth - President and CEO Jim Hippel - CFO Conference Call Participants Dan Arias - Stifel Catherine Schulte - Baird Jacob Johnson - Stephens John Leonard - Wells Fargo Patrick Donnelly - Citi Alex Nowak - Craig Hallum Partners Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | WHERE SCIENCE INTERSECTS INNOVATION | | | | | | | | | Corporate Presentation January 2020 | | | | | | | | | | | | | | | | | | | | | | | | | © 2020 Bio-Techne®. All rights reserved. SAFE HARBOR STATEMENT Cautionary Statements This presentation contains "forward-looking s ...

| --- | --- | --- | --- | --- | --- | --- | |-------|---------------|---------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | WHERE SCIENCE INTERSECTS INNOVATION | | | | | | | November 2019 | Corporate Presentation | | | | | | | | | | | | | © 2019 Bio-Techne®. All rights reserved. ANTIBODIES PROTEINS © 2019 Bio-Techne®. All rights reserved. 2 | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: For the quarterly period ended September 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...

Bio-Techne Corporation (NASDAQ:TECH) Q1 2020 Earnings Conference Call October 29, 2019 9:00 AM ET Company Participants David Clair - Senior Director, Corporate Development Charles Kummeth - President and CEO Jim Hippel - CFO Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Robert W. Baird Unidentified Analyst - Craig-Hallum Capital Group Paul Knight - Janney Montgomery Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction of inco ...

Financial Performance - The company achieved a record fiscal year with double-digit annual organic growth of 10.5% for fiscal 2019, marking the first year of such growth [7][50] - In Q4, reported revenue was $191.7 million, an increase of 6% year-over-year, with organic revenue growth of 7% [49][50] - Adjusted EPS for Q4 was $1.25, down from $1.34 a year ago, while GAAP EPS was $0.42 compared to $1.08 in the prior year [49][50] - Total company adjusted gross margin was 71.9% in Q4, relatively flat compared to the prior year [52] Business Segment Performance - The Protein Sciences segment reported Q4 sales of $143.4 million, with organic growth of 9% and operating margin of 45.4% [60][61] - The Diagnostics and Genomics segment had Q4 sales of $48.5 million, an increase of 4%, with organic growth of 2% [62] - The Simple Plex platform achieved growth rates of nearly 50% in the past year, becoming increasingly material to the company [20] Geographic Performance - North America experienced mid-teens organic growth for both the quarter and the full year, while Europe faced challenges with low-single-digit growth [10][50] - China saw over 20% growth in Q4 and over 25% for the full year, driven by strong demand and government support [14][98] Company Strategy and Industry Competition - The company plans to build a $50 million GMP proteins factory in Minnesota to support the growing cell and gene therapy market, expecting this division to reach at least $200 million in revenue in five years [27][75] - The company is focused on expanding its presence in the diagnostics market through acquisitions and new product offerings, including the Exosome Diagnostics platform [35][36] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit organic growth in fiscal 2020, despite headwinds from foreign exchange and investments in new business segments [119][122] - The company anticipates that the operating margin will remain flat year-over-year due to various headwinds, but core businesses are expected to continue improving productivity [119][122] Other Important Information - The company has made significant progress with its EPI test for prostate cancer, achieving over 25,000 tests performed and receiving breakthrough device designation from the FDA [41][42] - The company is actively working on expanding its product offerings in the cell and gene therapy space, with several preclinical studies underway [114] Q&A Session Summary Question: Long-term expectations for Europe - Management expects high-single-digit growth in Europe moving forward, despite recent challenges [81][82] Question: Outlook for glucose products - The glucose controls business is not strategic and is expected to stabilize at under $10 million, with mid to high-single-digit growth anticipated in other segments [83][85] Question: EPI test market opportunity - Management is optimistic about the EPI test's potential, with ongoing discussions for reimbursement and a strong growth trajectory expected [94][102] Question: Performance in China - The company anticipates continued strong growth in China, potentially exceeding 20% [98] Question: Future of cell and gene therapy - Management sees the cell and gene therapy division potentially generating $200 million to $300 million in revenue within five years, with ongoing investments to support this growth [107][117]

Click to edit Master title style biotechne® Corporate Presentation June 2019 Business Overview B U S I N E S S O V E R V I E W C O R P O R A T E Legacy Revenue At a Glance: | --- | --- | --- | |------------------------------------|-------|-------| | | | | | | | | | President and CEO: Chuck Kummeth | | | | Headquarters: Minneapolis, MN | 25% | | | Number of Employees: ~2,100 | | | | World Wide Presence: 35 Locations | | | | FY2018 Revenues: $643 million | | | | NASDAQ: TECH | 10% | | | Market Cap: ~$7B | | 6 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...

Bio-Techne Corp (NASDAQ:TECH) Q3 2019 Earnings Conference Call April 30, 2019 9:00 AM ET Company Participants James Hippel - SVP, Finance & CFO Charles Kummeth - CEO, President & Director Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Robert W. Baird & Co. Michael Sarcone - Deutsche Bank Charles Steinman - Goldman Sachs Group Alexander Nowak - Craig-Hallum Capital Group Operator Good morning, and welcome to Bio-Techne Earnings Conference Call for the third quarter of fiscal year ...